Premium
Thyroperoxidase antibodies and polycystic ovarian morphology
Author(s) -
Ramezani Tehrani Fahimeh,
Bahri Khomami Mahnaz,
Amouzegar Atieh,
Azizi Fereidoun
Publication year - 2016
Publication title -
international journal of gynecology and obstetrics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.895
H-Index - 97
eISSN - 1879-3479
pISSN - 0020-7292
DOI - 10.1016/j.ijgo.2016.01.016
Subject(s) - medicine , thyroid peroxidase , antibody , gynecology , immunology
Objective To evaluate the association between polycystic ovarian morphology (PCOM) and thyroperoxidase antibody level. Methods A cross‐sectional study was undertaken of women aged 15–49 years living in one of four provinces in Iran recruited between February 2009 and November 2010. Eligible women did not have hirsutism and were eumenorrheic. All participants underwent a comprehensive interview, clinical examination, blood sampling, and ultrasonographic assessment. The serum concentration of thyroperoxidase antibodies was compared between women with and without PCOM. Results Among 491 participants, 74 (15.1%) had PCOM. In total, 11 (14.9%) women with PCOM and 61 (14.6%) women with normal morphology tested positive for thyroperoxidase antibodies. The serum concentration of thyroperoxidase antibodies was higher among women with PCOM (48.45 ± 135.74 IU/mL) than among those with normal ovarian morphology (37.99 ± 96.49 IU/mL), but the difference was not significant ( P = 0.42). Conclusion Thyroperoxidase antibody levels were higher in Iranian women with PCOM than in women with normal morphology, although the difference was not significant. Larger longitudinal studies are needed to investigate whether the treatment of thyroid disorders can prevent the development of PCOM.